The Syneos Health Podcast | Conversations on Commercialization
Commercialization is becoming more tightly connected to decisions across the biopharma journey, from value and access to launch strategy, deployment and patient, provider and advocacy engagement.
Conversations on Commercialization is the latest addition to the Syneos Health Podcast family, featuring leaders and experts from across the industry discussing the strategies, challenges and shifts shaping commercial success in today’s market. Each episode explores how companies are approaching the issues that matter most in commercialization and what it takes to compete more effectively in today’s market.
Subscribe to The Syneos Health Podcast: Conversations on Commercialization for new episodes.
If there’s a topic you’d like us to explore, send us a message at [email protected].
The views expressed in this podcast belong solely to the speakers and do not represent those of their organizations.
Want to be notified when new episodes are released?
Episode 5: Navigating Dermatology’s New Access Landscape with Paul Rittman of Almirall US
In this episode, Tyler Cowan, VP, Commercial at Syneos Health speaks with Paul Rittman, President and General Manager of Almirall US, about how payer consolidation and PBM influence are reshaping dermatology commercialization.
They discuss how pharmaceutical companies must adapt launch strategy, market access planning and clinical differentiation to succeed in today’s competitive specialty landscape. The conversation explores the growing role of digital engagement, direct-to-consumer (DTC) strategy, telehealth and cash-pay models in improving patient access.
Listeners will gain practical insights into how innovation, payer strategy and patient-centric commercialization drive success in dermatology and specialty pharma.
Episode 4: Changing the Name Game with Addison Whitney’s Ari™
What if drug naming could be faster, smarter and more aligned to brand strategy?
In this episode, Addison Whitney's Joe Daley, President and Bill Purdy, SVP and Managing Director, break down how Ari™, a purpose-built AI platform, is solving long-standing naming and branding challenges in biopharma.
Listen and learn:
- How Ari™ integrates strategic input, trademark search and POCA screening
- Ways AI reduces attrition and regulatory risk in naming
- Why naming is now a strategic process and not just a creative one
Episode 4: Changing the Name Game with Addison Whitney’s Ari™
What if drug naming could be faster, smarter and more aligned to brand strategy?
In this episode, Addison Whitney's Joe Daley, President and Bill Purdy, SVP and Managing Director, break down how Ari™, a purpose-built AI platform, is solving long-standing naming and branding challenges in biopharma.
Listen and learn:
- How Ari™ integrates strategic input, trademark search and POCA screening
- Ways AI reduces attrition and regulatory risk in naming
- Why naming is now a strategic process and not just a creative one
Episode 3: GLP-1 Gold Rush — Who’s Really Winning in the New Obesity Market?
Host Tyler Cowan, VP Commercial at Syneos Health, joins Hruta Shah, Senior Engagement Manager for Syneos Health Consulting, to break down the high-stakes race in obesity treatment and the commercial boom around GLP-1 therapies.
You’ll hear:
- What emerging launch strategies look like in a crowded pipeline and how success is being redefined
- How GLP-1s are accelerating a shift in stakeholder dynamics, including telehealth, large employers and direct-to-patient platforms
- Why traditional DTC advertising is evolving and how informed patients are influencing brand messaging
Episode 2: DTP, AI and the Future of Pharma Access
In part two of our conversation with Mark Bard, he and Tyler Cowan turn the lens to patients, exploring how direct-to-patient models are disrupting traditional care and the implications of reduced physician involvement. They also tackle the rise of agentic AI, what it could enable and what commercial teams should be thinking about now.
Episode 1: The New Rules of HCP Engagement
Mark Bard, Co-Founder of Digital Health Coalition (DHC) joins host Tyler Cowan, VP, Commercial at Syneos Health, to unpack how the pandemic reshaped provider expectations and the continued impact on commercial teams. From feedback loops to content fatigue, to the myth of multichannel mastery, they break down what it takes to engage HCPs on their terms.
